Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.33 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.32 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210438 | 0.93 | CHIT1 (0.35) | PDE4DMMP2MMP9MMP13CHIT1 | |
| SCHEMBL12209418 | 0.91 | PDE4D (0.35) | PDE4DTNFEHMT2EHMT1 | |
| SCHEMBL10283434 | 0.91 | PDE4D (0.35) | PDE4DTNFEHMT2EHMT1 | |
| SCHEMBL973495 | 0.91 | PDE4D (0.35) | PDE4DTNFEHMT2EHMT1SRC | |
| SCHEMBL973669 | 0.91 | PDE4D (0.35) | PDE4DEGLN1TNFEHMT2EHMT1 | |
| SCHEMBL8058110 | 0.91 | PDE4D (0.42) | PDE4DKMT2ATNFEHMT2EHMT1 | |
| SCHEMBL10266532 | 0.91 | PDE4D (0.35) | PDE4DTNFEHMT2EHMT1 | |
| SCHEMBL12921249 | 0.91 | PDE4D (0.41) | PDE4DKMT2AMMP2MMP9MMP13 | |
| SCHEMBL8051590 | 0.90 | PDE4D (0.36) | PDE4DTNFEHMT2EHMT1 | |
| SCHEMBL589081 | 0.90 | MAPT (0.38) | PDE4DMEN1KMT2ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400962-B1 | Medicinal combinations containing PDE4 inhibitors and NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-08 | — | — | EP | claimed |
| EP-2555774-B1 | Medicine combinations containing pde4 inhibitors and ep4 receptor antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-10-21 | — | — | EP | claimed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | claimed |
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | claimed |
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | claimed |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | claimed |
| EP-2400962-B1 | Medicinal combinations containing PDE4 inhibitors and NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-08 | — | — | EP | disclosed |
| EP-2400962-B1 | Medicinal combinations containing PDE4 inhibitors and NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-08 | — | — | EP | disclosed |
| EP-2555774-B1 | Medicine combinations containing pde4 inhibitors and ep4 receptor antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-10-21 | — | — | EP | disclosed |
| EP-2555774-B1 | Medicine combinations containing pde4 inhibitors and ep4 receptor antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| EP-2380891-A1 | Substituted piperidino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011124525-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | WO | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2010097334-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009050248-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | PTGER4, PTGER1, PDE4A | PDE4D 26/4885MEN1 4030/4885KMT2A 3334/4885 |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | PTGER4, PTGER1, PDE4A | PDE4D 26/4885MEN1 4030/4885KMT2A 3334/4885 |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PDE4A, PDE12, PDE3B | PDE4D 16/4885MEN1 3783/4885KMT2A 3945/4885 |
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | PDE4B, PDE3B, PDE4A | PDE4D 9/4885MEN1 2273/4885KMT2A 2236/4885 |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | PDE4D 2859/4885MEN1 2165/4885KMT2A 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.